US 10851377
Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder
granted A61KA61K31/7115A61K31/713
Quick answer
US patent 10851377 (Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder) held by Alnylam Pharmaceuticals, Inc. expires Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Alnylam Pharmaceuticals, Inc.
- Grant date
- Tue Dec 01 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Nov 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 30
- CPC classes
- A61K, A61K31/7115, A61K31/713, A61K39/3955, A61K45/06